Rakesh Patel - Icad Director
| ICAD Stock | USD 1.56 0.04 2.50% |
Director
Dr. Rakesh Patel is Director of the Company. Dr. Rakesh Patel has served as medical director of Radiation Oncology and Chair of the MultiDisciplinary Breast Care Program at Good Samaritan Hospital since July 2013. In addition, he has served as cofounder of the TME Breast Care Network, a highend physician peertopeer knowledgesharing, research, education and consulting company, since January 2013. Dr. Patel has also served as Chief Executive Officer of Precision Cancer Specialists Medical Group, an organization whose core mission is to improve quality and access to advanced, targeted radiation therapy, since December 2016. He previously served on the board of directors of Radion, Inc., a company that improved quality of access for patients and doctors with an innovative ecollaboration platform, the assets of which were acquired by the Company in July 2014. Prior to that, Dr. Patel was the founder and served on the board of directors of BrachySolutions, Inc., a telehealth company whose mission was to improve quality and access to advanced brachytherapy globally via custom elearning modules. He holds a BS degree from the University of Notre Dame and an M.D. from Indiana University School of Medicine since 2018.
| Age | 44 |
| Tenure | 6 years |
| Professional Marks | Ph.D |
| Address | 98 Spit Brook Road, Nashua, NH, United States, 03062 |
| Phone | 603 882 5200 |
| Web | https://www.icadmed.com |
Icad Management Efficiency
The company has return on total asset (ROA) of (0.1032) % which means that it has lost $0.1032 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2052) %, meaning that it created substantial loss on money invested by shareholders. Icad's management efficiency ratios could be used to measure how well Icad manages its routine affairs as well as how well it operates its assets and liabilities. As of April 18, 2024, Return On Tangible Assets is expected to decline to -0.24. In addition to that, Return On Capital Employed is expected to decline to -0.23. At present, Icad's Non Current Assets Total are projected to decrease significantly based on the last few years of reporting. The current year's Fixed Asset Turnover is expected to grow to 11.18, whereas Other Current Assets are forecasted to decline to about 681 K.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Keith Valentine | Si Bone | 50 | |
| MBA PharmD | Biomerica | N/A | |
| Samuel Navarro | STRATA Skin Sciences | ||
| Francis Cano | Biomerica | 73 | |
| Alan Levine | Axogen Inc | 50 | |
| Robert Rudelius | Axogen Inc | 62 | |
| George Philip | Paragon 28 | 67 | |
| Mike Donovan | Axogen Inc | 53 | |
| Brian Dempsey | Paragon 28 | 36 | |
| Lisa Colleran | Axogen Inc | 59 | |
| Marat Garaev | Si Bone | 44 | |
| Mark Gold | Axogen Inc | 69 | |
| Susan Harnett | Paragon 28 | 57 | |
| Aristeidis Iliopoulos | Profound Medical Corp | 34 | |
| Elena Mikhaylova | Si Bone | 41 | |
| Konstantinos Mantzavinatos | Profound Medical Corp | 53 | |
| Rox Anderson | STRATA Skin Sciences | N/A | |
| David Bonita | Si Bone | 42 | |
| Mark Reiley | Si Bone | 67 | |
| Timothy Davis | Si Bone | 48 | |
| Nikolay Dubik | Si Bone | 45 | |
Management Performance
| Return On Equity | -0.21 | ||||
| Return On Asset | -0.1 |
icad inc Leadership Team
Elected by the shareholders, the Icad's board of directors comprises two types of representatives: Icad inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Icad. The board's role is to monitor Icad's management team and ensure that shareholders' interests are well served. Icad's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Icad's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Andrew Sassine, Director | ||
| Stephen Sarno, Interim Officer | ||
| Michelle Strong, Chief Officer | ||
| Jonathan Go, Sr. VP of RandD | ||
| Zack Kubow, IR Contact Officer | ||
| Scott Areglado, Vice President Controller | ||
| Brian Testa, Chief Officer | ||
| Susan Wood, Director | ||
| Richard Christopher, CFO, Executive Vice President | ||
| Vasu Avadhanula, Chief Officer | ||
| Lawrence Howard, Chairman of the Board | ||
| Anthony Takazawa, Director Relations | ||
| Robert Goodman, Director | ||
| Elliot Sussman, Independent Director | ||
| Dana Brown, CEO President | ||
| Kevin Burns, President, CFO, COO, Treasurer and Secretary | ||
| Somu Subramaniam, Independent Director | ||
| Rakesh Patel, Director | ||
| Eric Lonnqvist, Chief Officer | ||
| Steven Rappaport, Independent Director | ||
| Annette Heroux, Vice Administration | ||
| Michael Klein, Ex Director | ||
| Stacey Stevens, Sr. VP of Marketing and Strategy | ||
| Anthony Ecock, Independent Director | ||
| Rachel Brem, Independent Director | ||
| Jeffrey Sirek, Chief Officer | ||
| Kenneth Ferry, CEO and Director | ||
| Bill Keyes, Senior Operations | ||
| Peter Graham, Senior Sales |
Icad Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Icad a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.21 | ||||
| Return On Asset | -0.1 | ||||
| Profit Margin | (0.28) % | ||||
| Operating Margin | (0.15) % | ||||
| Current Valuation | 20.96 M | ||||
| Shares Outstanding | 26.35 M | ||||
| Shares Owned By Insiders | 5.80 % | ||||
| Shares Owned By Institutions | 28.53 % | ||||
| Number Of Shares Shorted | 451.27 K | ||||
| Price To Earning | (8.32) X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in icad inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. Note that the icad inc information on this page should be used as a complementary analysis to other Icad's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Complementary Tools for Icad Stock analysis
When running Icad's price analysis, check to measure Icad's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Icad is operating at the current time. Most of Icad's value examination focuses on studying past and present price action to predict the probability of Icad's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Icad's price. Additionally, you may evaluate how the addition of Icad to your portfolios can decrease your overall portfolio volatility.
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets |
Is Icad's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Icad. If investors know Icad will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Icad listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.27) | Revenue Per Share 0.676 | Quarterly Revenue Growth 0.023 | Return On Assets (0.10) | Return On Equity (0.21) |
The market value of icad inc is measured differently than its book value, which is the value of Icad that is recorded on the company's balance sheet. Investors also form their own opinion of Icad's value that differs from its market value or its book value, called intrinsic value, which is Icad's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Icad's market value can be influenced by many factors that don't directly affect Icad's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Icad's value and its price as these two are different measures arrived at by different means. Investors typically determine if Icad is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Icad's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.